Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)-Reference-Cited by-同舟云学术

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Published:2009-07 Issue:9683 Volume:374 Page:39-47
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Buse John B,Rosenstock Julio,Sesti Giorgio,Schmidt Wolfgang E,Montanya Eduard,Brett Jason H,Zychma Marcin,Blonde Lawrence

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus algorithm for the initiation and adjustment of therapy;Nathan;Diabetes Care,2008

2. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age;Tourrel;Diabetes,2001

3. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway;Hui;Endocrinology,2003

4. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats;Perfetti;Endocrinology,2000

5. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo;Deacon;J Clin Endocrinol Metab,1995

Cited by 1245 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the therapeutic potential of xanthones in diabetes management: Current insights and future directions;European Journal of Medicinal Chemistry Reports;2024-12

2. Incretin therapy in feline diabetes mellitus – A review of the current state of research;Domestic Animal Endocrinology;2024-10

3. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

4. GLP-1R–positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice;Journal of Clinical Investigation;2024-09-03

5. Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future;Medicinal Research Reviews;2024-08-14